Kimberly-Clark is preparing concessions to address European Union antitrust concerns over its $40 billion acquisition of Kenvue, potentially helping the deal secure approval after a preliminary review. The European Commission, the EU’s competition enforcer, is set to notify Kimberly-Clark of its concerns this week, people familiar with the matter said. Announced in November last year, the transaction would add Kenvue brands including Tylenol, Listerine, Aveeno and Neutrogena to Kimberly-Clark’s portfolio, which includes Kleenex and Huggies.